Literature DB >> 6141599

Modulation of CNS dopamine receptors by peptides.

R K Mishra.   

Abstract

L-prolyl-L-leucyl-glycinamide (PLG), when administered concurrently with neuroleptic drug, blocked the development of dopamine receptor supersensitivity both at the behavioral and biochemical level. Chronic administration of haloperidol resulted in development of cholecystokinin (CCK) receptor supersensitivity in the mesolimbic regions of the brain. There was no change in equilibrium dissociation constant (KD) for CCK binding. The results are discussed in relation to modulation of dopamine receptor by peptides and possible models of interaction of peptides with dopamine receptors are proposed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141599     DOI: 10.1016/0278-5846(83)90008-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  2 in total

1.  PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia.

Authors:  Bailee Dyck; Kelly Guest; Christal Sookram; Dipannita Basu; Rodney Johnson; Ram K Mishra
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

2.  Substance P analogs displace sigma binding differentially in the brain and spinal cord of the adult mouse.

Authors:  D D Mousseau; A A Larson
Journal:  Metab Brain Dis       Date:  1994-09       Impact factor: 3.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.